Drug safety evaluation of rotigotine

Expert Opinion on Drug Safety

Volumn 11, Issue 3, 2012, Pages 503-512

  Sprenger, Fabienne Stephanie ^a   Seppi, Klaus ^a   Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Idiopathic Parkinson's disease; Restless legs syndrome; Rotigotine; Safety

Indexed keywords

LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ANOREXIA; ANXIETY DISORDER; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CONSTIPATION; COUGHING; DEPRESSION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; FATIGUE; HALLUCINATION; HUMAN; HYPERHIDROSIS; IDIOPATHIC DISEASE; IDIOPATHIC PARKINSON DISEASE; INFLUENZA; INSOMNIA; NARCOLEPSY; NAUSEA; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; PARKINSON DISEASE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; TACHYCARDIA; TREMOR; UNCONSCIOUSNESS; VOMITING; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ANTIPARKINSON AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOPAMINE AGONISTS; EVIDENCE-BASED MEDICINE; HUMANS; PARKINSON DISEASE; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 84860125816     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.678830     Document Type: Article

References (33)

1. Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994;9:147-54 (Pubitemid 24092329)
2. Horn AS, Tepper P, Van der Weide J, et al. Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist. Pharm Weekbl Sci 1985;7:208-11 (Pubitemid 15225084)
3. Van der Weide J, Tendijck ME, Tepper PG, et al. The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre-and postsynaptic dopamine receptors. Eur J Pharmacol 1988;146:319-26 (Pubitemid 18068508)
4. Timmerman W, Westerink BH, De Vries JB, et al. Microdialysis and striatal dopamine release: stereoselective actions of the enantiomers of N-0437. Eur J Pharmacol 1989;162:143-50 (Pubitemid 19074887)
5. Swart PJ, De Zeeuw RA. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie 1992;47:613-15
6. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005;65:S3-5 (Pubitemid 41022399)
7. Pfeiffer RF. A promising new technology for Parkinson's disease. Neurology 2005;65:S6-10
8. Guldenpfennig WM, Poole KH, Sommerville KW, et al. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 2005;28:106-10 (Pubitemid 40923407)
9. Baldwin CM, Keating GM. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease. CNS Drugs 2007;21:1039-55 (Pubitemid 350136786)
10. Boroojerdi B, Wolff HM, Braun M, et al. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Drugs Today (Barc) 2010;46:483-505
11. Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009;37:2055-60
12. Braun M, Cawello W, Andreas JO, et al. Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. J Clin Pharmacol 2009;49:1047-55
13. Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine [abstract]. J Clin Pharmacol 2005;45:1091
14. Cawello W, Wolff HM, Meuling WJ, et al. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokinet 2007;46:851-7 (Pubitemid 47443309)
15. Braun M, Cawello W, Poole KH, et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. Eur J Neurol 2005;12(Suppl 2):96
16. Cawello W, Braun M, Horstmann R. Impact of moderate impairment of hepatic function on steady-state pharmacokinetics of transdermal rotigotine. Eur J Neurol 2007;14(Suppl 1):199
17. Cawello W, Braun M, Horstmann R. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function. J Clin Pharmacol 2005;45:1091
18. Braun M, Cawello W, Boekens H, et al. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol 2009;67:209-15
19. Braun M, Elshoff JP, Andreas JO, et al. Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive. Br J Clin Pharmacol 2009;68:386-94
20. Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009;379:73-86
21. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-6 (Pubitemid 46148338)
22. PSG. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-8
23. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-404 (Pubitemid 351155987)
24. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68:1262-7 (Pubitemid 46625971)
25. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9
26. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20 (Pubitemid 46734759)
27. Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-56
28. Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675-83
29. Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-39 (Pubitemid 351391727)
30. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
31. Oertel WH, Benes H. Garcia-Borreguero, et al. Long-term safety and efficacy of rotigotine transdermal system in moderate to severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011;10(8):710-20
32. Hogl B, Oertel WH, Stiasny-Kolster K, et al. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol 2010;10:86
33. Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial. BMC Neurol 2007;7:20